Literature DB >> 18242923

Acute colonic pseudo-obstruction: rapid correction with neostigmine in the emergency department.

Robert McNamara1, Michael J Mihalakis.   

Abstract

Ogilvie's syndrome, now known as acute colonic pseudo-obstruction, is characterized by massive dilatation of large bowel in the absence of mechanical obstruction. It is found in a variety of patients, although elderly and immobile patients make up a large portion of the afflicted population. This article discusses the case of a 64-year-old bedridden, paraplegic, male nursing home resident who presented to the Emergency Department with a chronic history of abdominal distention that acutely worsened on the day of his arrival. A diagnosis of acute colonic pseudo-obstruction was made and 2 mg of intravenous neostigmine was administered, with resolution of the patient's condition allowing for subsequent Emergency Department discharge. This report discusses the utilization of neostigmine, an acetylcholinesterase inhibitor, for patients with colonic pseudo-obstruction. We also briefly review the literature on this condition and other therapeutic options.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18242923     DOI: 10.1016/j.jemermed.2007.06.043

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  10 in total

1.  Wilkie or Ogilvie?

Authors:  Avi Ohry
Journal:  Spinal Cord Ser Cases       Date:  2018-10-27

2.  Neostigmine for the treatment of acute colonic pseudo-obstruction (ACPO) in pediatric hematologic malignancies.

Authors:  Jae-Wook Lee; Kyong-Won Bang; Pil-Sang Jang; Nak-Gyun Chung; Bin Cho; Dae-Chul Jeong; Hack-Ki Kim; Soo-Ah Im; Gye-Yeon Lim
Journal:  Korean J Hematol       Date:  2010-03-31

3.  Massive acute colonic pseudo-obstruction successfully managed with conservative therapy in a patient with cerebral palsy.

Authors:  Derek R Cooney; Norma L Cooney
Journal:  Int J Emerg Med       Date:  2011-04-14

4.  The Association of Coloproctology of Great Britain and Ireland consensus guidelines in emergency colorectal surgery.

Authors:  Andrew S Miller; Kathryn Boyce; Benjamin Box; Matthew D Clarke; Sarah E Duff; Niamh M Foley; Richard J Guy; Lisa H Massey; George Ramsay; Dominic A J Slade; James A Stephenson; Phil J Tozer; Danette Wright
Journal:  Colorectal Dis       Date:  2021-02       Impact factor: 3.917

5.  Evaluation of intravenous neostigmine infusion on tolerance of enteral nutrition in Intensive Care Unit patients.

Authors:  Omid Aghadavoudi; Saeed Abbasi; Parviz Kashefi; Mohammad Golparvar; Mohammadreza Habibzade; Shadi Kazemi
Journal:  J Res Med Sci       Date:  2013-09       Impact factor: 1.852

6.  Acute Colonic Pseudo-Obstruction with Feeding Intolerance in Critically Ill Patients: A Study according to Gut Wall Analysis.

Authors:  Chenyan Zhao; Tingbin Xie; Jun Li; Minhua Cheng; Jialiang Shi; Tao Gao; Fengchan Xi; Juanhong Shen; Chun Cao; Wenkui Yu
Journal:  Gastroenterol Res Pract       Date:  2017-03-12       Impact factor: 2.260

7.  Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility.

Authors:  J Broad; V W S Kung; G Boundouki; Q Aziz; J H De Maeyer; C H Knowles; G J Sanger
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

8.  The use of intravenous neostigmine in palliation of severe ileus.

Authors:  Pashtoon Murtaza Kasi
Journal:  Case Rep Gastrointest Med       Date:  2013-02-14

9.  Polypyridylruthenium(II) complexes exert anti-schistosome activity and inhibit parasite acetylcholinesterases.

Authors:  Madhu K Sundaraneedi; Bemnet A Tedla; Ramon M Eichenberger; Luke Becker; Darren Pickering; Michael J Smout; Siji Rajan; Phurpa Wangchuk; F Richard Keene; Alex Loukas; J Grant Collins; Mark S Pearson
Journal:  PLoS Negl Trop Dis       Date:  2017-12-14

Review 10.  Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment.

Authors:  Ondrej Soukup; Michael Winder; Uday Kumar Killi; Vladimir Wsol; Daniel Jun; Kamil Kuca; Gunnar Tobin
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.